In 2017, several high-impact studies in thrombosis were published. Refinements were made in the optimal therapy for patients with stable atherosclerosis or with atrial fibrillation undergoing percutaneous coronary intervention. Risk scores to determine duration of antiplatelet therapy were developed. The potential risk of subclinical valve leaflet thrombosis was identified.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bosch, J. et al. Rationale, design and baseline characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can. J. Cardiol. 33, 1027–1035 (2017).
Eikelboom, J. W. et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N. Engl. J. Med. 377, 1319–1330 (2017).
Connolly, S. J. et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32458-3 (2017).
Anand, S. S. et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(17)32409-1 (2017).
Cannon, C. P. et al. Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin. Cardiol. 39, 555–564 (2016).
Cannon, C. P. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med. 377, 1513–1524 (2017).
Costa, F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 389, 1025–1034 (2017).
Makkar, R. R. et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N. Engl. J. Med. 373, 2015–2024 (2015).
Mangione, F. M. et al. Leaflet thrombosis in surgically explanted or post-mortem TAVR valves. JACC Cardiovasc. Imaging 10, 82–85 (2017).
Chakravarty, T. et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 389, 2383–2392 (2017).
D.L.B. declares the following relationships. Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences. Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care. Chair: American Heart Association Quality Oversight Committee. Data Monitoring Committees: Cleveland Clinic, Duke Clinical Research Institute, Harvard Clinical Research Institute (PORTICO DSMB), Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute. Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (RE-DUAL executive committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (COMPASS steering committee, operations committee, publications committee, and US national co-leader), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees). Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair). Research Funding: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company. Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease). Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott). Trustee: American College of Cardiology. Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda.
About this article
Cite this article
Bhatt, D. Advances in atherosclerosis, atrial fibrillation, and valvular disease. Nat Rev Cardiol 15, 71–72 (2018). https://doi.org/10.1038/nrcardio.2017.212
Journal of Cardiovascular Pharmacology and Therapeutics (2020)
Nature Reviews Cardiology (2018)